Adaptions to therapeutic pressures exerted on cancer cells enable malignant progression of
the tumor, culminating in escape from programmed cell death and development of resistant …

ROS1 is a proto-oncogene encoding a receptor tyrosine protein kinase (RTK), homologous
to the v–Ros sequence of University of Manchester tumours virus 2 (UR2) sarcoma virus …

Background: Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase
inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal …

Simple Summary In recent years, prognosis of non-small cell lung cancer (NSCLC) patients
significantly improved thanks to the introduction of tyrosine kinase inhibitors (TKIs) in clinical …

Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and
therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1 …

Background Targeted therapies directed at specific driver oncogenes have improved
outcomes for individuals with advanced non‐small cell lung cancer (NSCLC). Approximately …

Mechanistically, chimeric genes result from DNA rearrangements and include parts of
preexisting normal genes combined at the genomic junction site. Some rearranged genes …

ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In
the present work, we have performed a QSAR analysis on a dataset of 224 molecules in …

Simple Summary Lung cancer is the leading cause of cancer related deaths worldwide, with
a relatively low 5-year survival rate. Although there are many therapies against lung cancer …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for
almost 80%–85% of all lung cancer cases. Unfortunately, more than half of the patients will …